WALTHAM, Mass. – January 4, 2019 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) drug discovery engine to the generation of novel small molecule therapeutics, today announced the expansion of its collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX).
WALTHAM, Mass. – December 18, 2018 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) library drug discovery engine to the generation of novel small molecule therapeutics, today announced the signing of a broad strategic drug discovery collaboration with Bristol-Myers Squibb.
WALTHAM, Mass. – December 12, 2018 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Almirall, S.A. (Almirall) to discover lead compounds for innovative and challenging targets with dermatology applications.
WALTHAM, Mass. – July 26, 2018 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEXTM) library drug discovery engine to the generation of novel small molecule therapeutics, today announced that it has licensed its 10th drug discovery program to date in 2018, bringing the total number of licensed programs […]
WALTHAM, Mass. April 24, 2018 – Small molecule drug discovery specialist X-Chem, Inc. (XChem) today announced that its spin-out company X-Biotix Therapeutics, Inc. (X-Biotix) has secured $7 million in a Series A financing from a group of private investors. X-Biotix, launched in 2017 out of X-Chem by Ramani Varanasi, Ph.D. and faculty members in the […]
X-Chem, Inc. today announced the appointment of Christelle Huguet, Ph.D. as Chief Scientific Officer, along with an executive leadership appointment for Matthew Clark, Ph.D. as Senior Vice President, Chemistry.
Small molecule drug discovery specialist XChem, Inc. today announced that AbbVie has exercised options to license two discovery programs. Under the terms of the parties’ 2016 multi-target research collaboration, AbbVie had an option to an exclusive license to the programs, each of which comprises multiple novel, cell-active modulators of two historically challenging targets in oncology […]
Agonists and Antagonists of Protease-Activated Receptor 2 Discovered within a DNA-Encoded Chemical Library Using Mutational Stabilization of the Target
WALTHAM, Mass. – January 17, 2018 – Small molecule discovery specialist X-Chem, Inc. today announced a significant expansion of their existing global drug discovery collaboration with the global biopharmaceutical company AstraZeneca.
X-Chem, Inc. announces that it has licensed its 40th drug discovery program to an undisclosed large Pharma partner, granting exclusive rights to novel small molecules that interact with the partner’s therapeutic target of interest.
